Calypte Appoints Dr. Ronald W. Mink Chief Science Officer
Dr. Toby Gottfried retires
PLEASANTON, Calif., July 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has promoted Dr. Ronald W. Mink to the position of Chief Science Officer (CSO), replacing Dr. Toby Gottfried who retired in June of this year. Prior to being appointed as Chief Scientific Officer, Dr. Mink served as Director of R&D at Calypte.
Dr. Richard George, President and CEO of Calypte said, "Dr. Mink has over 20 years of experience in the development and commercialization of rapid assays and has been instrumental in the development and commercialization of Calypte's rapid tests. Most recently he led the successful effort of setting up the Company's manufacturing in Thailand where we just completed the technology transfer of our blood and oral fluid rapid HIV-1/2 products, and he will lead the China effort in the coming months. Prior to joining Calypte, he was the Director of Research and Development at OraSure Technologies, Inc. (Nasdaq: OSUR). At OraSure, Dr. Mink was the inventor of the first OraQuick HIV-1 rapid prototypes (U.S. Patent 6,303,081), supervised the OraQuick research and development effort and oversaw product transfer to production. Prior experience in the rapid develop arena includes such companies as Eli Lilly and Co. in their diagnostic group and Carter Wallace. Dr. Mink is well suited in this new role."
Dr. George added, "Toby has been with Calypte since its inception in the late 1980's and has guided the development of the company over the years. I want to personally thank her for all of her contributions ... and I am very pleased to note, that while Toby is retiring, she is still willing to share her knowledge and skills with the company and will support us as necessary in a consulting capacity."
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact:
Richard George, President and CEO Tim Clemensen,
(925) 730-7200 Rubenstein Investor Relations
email: rgeorge@calypte.com Phone: (212) 843-9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
Richard George, President and CEO of Calypte Biomedical Corporation, +1-925-730-7200
rgeorge@calypte.com; Investor Relations - Tim Clemensen of Rubenstein Investor
Relations, +1-212-843-9337, tclemensen@rubensteinir.com, for Calypte Biomedical
Corporation
http://www.prnewswire.com
Gruß
C.O |
Thread abonnieren
